Cost-effectiveness of Tamoxifen, Aromatase Inhibitor, and Switch Therapy (Adjuvant Endocrine Therapy) for Breast Cancer in Hormone Receptor Positive Postmenopausal Women in India.
Dimple ButaniNidhi GuptaSushmita GhoshalPankaj BahugunaRakesh KapoorShankar PrinjaPublished in: Breast cancer (Dove Medical Press) (2021)
In postmenopausal women with HR-positive early-stage breast cancer, switch therapy is recommended for use on the basis of cost-effectiveness.